AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis suggested that the combination led to reductions in bone marrow fibro
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1455323545-9132d19b253042298a5e50cebc341788.jpg "Credit Scams to Watch Out For")
:max_bytes(150000):strip_icc():format(jpeg)/InsuranceScorehowitworks-5a42f332494ec90036720943.jpg "What Credit Score Should You Have?")
:max_bytes(150000):strip_icc():format(jpeg)/documents3-2c9f0be43694417aa7a597ee195072f1.jpg "How Long Does an Item Appear on My Credit Report?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1190222745-b65de6b6c3b948d2a22db5d28c5b1fb8.jpg "Is My Credit Score Good Enough for a Mortgage?")